Plexium's Groundbreaking Research at AACR 2025
Plexium, Inc. is proud to announce multiple presentations at the upcoming AACR 2025 Annual Meeting. The company is recognized for its innovative approach to targeted protein degradation, focusing on selective monovalent degrader programs targeting SMARCA2, IKZF2, and CDK2.
One of the standout programs is PLX-61639, a selective oral SMARCA2 degrader. This drug has shown promising results in demonstrating sustained pharmacodynamic responses and efficacy as a single agent in tumors with SMARCA4 mutations. This program is currently progressing through IND-enabling studies, showcasing Plexium's commitment to advancing effective cancer therapies.
Another highlight is PLX-4545, a selective IKZF2 molecular glue degrader. In Phase 1 trials, it completely degraded IKZF2 across a range of well-tolerated doses, showing a shift from regulatory T cells (Tregs) to an effector-like T cell phenotype. This shift could significantly impact tumor growth inhibition and the effectiveness of concurrent immune checkpoint therapies.
Innovative Mechanisms and Preclinical Success
Plexium has presented preclinical data regarding its CDK2 selective molecular glue degrader. This candidate exhibited superior selectivity compared to traditional inhibitor-based approaches. The focus here is on cancers that are amplified for CCNE1, which are often aggressive and challenging to treat.
“These data illustrate the clinical and preclinical advancements we've achieved in our portfolio. We are particularly excited about our use of a novel E3 ligase, DCAF16, in our SMARCA2 program, which is a first in the industry,” commented Jorge F. DiMartino, MD, PhD, Chief Medical Officer at Plexium. The data shared reflects both the novelty and the differentiation of Plexium's targeted approach against cancer.
Presentation Details at AACR 2025
Plexium has organized a series of oral and poster presentations that will showcase their research advancements. Key presentations include:
Oral Presentation: "Discovery and Characterization of a Novel, Potent, and Selective CDK2 Molecular Glue Degrader Against CCNE1-Amplified Tumors"
Session: MS.ET09.01 – Degraders and Glues
Abstract Number: 6375
Date and Time: April 29, 2:55 PM – 3:10 PM
Presenting Author: Leenus Martin, PhD
Oral Presentation: "PLX-4545, a Selective IKZF2 Degrader, Reprograms Suppressive Tregs Leading to Tumor Growth Inhibition"
Session: MS.ET09.01 – Degraders and Glues
Abstract Number: 6380
Date and Time: April 29, 4:10 PM – 4:25 PM
Presenting Author: Peggy Thompson, PhD
Highlights from Poster Presentations
Additionally, Plexium will feature several poster presentations that detail their findings:
Poster Presentation: "Mechanistic Characterization of Selective Monovalent Direct Degraders of SMARCA2"
Session: PO.ET09.04 – Degraders and Glues 1
Abstract Number: 404
Date and Time: April 27, 2025, 2:00 PM – 5:00 PM
Presenting Author: Julia Toth, PhD
- Plexium's SMARCA2 degraders show efficacy via bromodomain binding and covalent modification.
- CRISPR knockout screening identified DCAF16 as essential for the degradation of SMARCA2.
- Studies indicated stable complex formation between PLX-61639, SMARCA2, and DCAF16, necessary for effective degradation.
Poster Presentation: "Preclinical Characterization of PLX-61639, a Potent and Orally Bioavailable SMARCA2-Selective Monovalent Direct Degrader"
Session: PO.ET09.10 – Degraders and Glues 2
Abstract Number: 1653
Date and Time: April 28, 2025, 9:00 AM – 12:00 PM
Presenting Author: Gregory Parker, PhD
- PLX-61639 has been nominated as a development candidate following impressive tumor growth inhibition results in preclinical models.
- Daily dosing has resulted in significant SMARCA2 degradation without altering control models.
- This candidate is making its way through essential IND-enabling studies.
Plexium's commitment to advancing cancer treatment through innovative approaches sets it apart in the therapeutic landscape. By focusing on actionable mechanisms, the company is strengthening its pipeline to target various cancers effectively.
About Plexium Inc.
As a leader in the realm of targeted protein degradation, Plexium is pushing the boundaries of drug discovery. The company employs advanced AI-integrated ultra-high-throughput drug discovery technologies to identify small molecules capable of inducing E3 ligase mediated selective degradation. This forward-thinking approach empowers Plexium to develop its monovalent degraders aimed at tackling cancer, neurodegeneration, and other critical diseases. Their commitment to innovation is shaping the future of therapeutic strategies.
Contact Information for Plexium:
Amy Conrad
Juniper Point
Phone: 858-366-3243
Frequently Asked Questions
What is the main focus of Plexium's presentations at AACR 2025?
Their presentations revolve around selective monovalent degrader programs targeting SMARCA2, IKZF2, and CDK2, highlighting novel approaches in cancer treatment.
How does PLX-61639 function?
PLX-61639 is designed as a selective SMARCA2 degrader that binds via bromodomain interactions, leading to effective protein degradation in specific tumor types.
What is unique about PLX-4545?
PLX-4545 is notable for reprogramming Tregs into effector-like T cells, which is essential in enhancing the immune response against tumors.
What recent results has Plexium shared?
Recent presentations at AACR 2025 include impressive clinical data showing efficacy and safety in both PLX-61639 and PLX-4545 trials.
How does Plexium approach drug discovery?
Plexium utilizes a proprietary AI-integrated drug discovery platform that enables the identification of novel small molecules for targeted protein degradation.
